Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Consolidated Statements of Operations
Grant and award revenue	$ 4,904	$ 5,174
Operating expenses
Research and development	23,717	34,426
General and administrative	12,409	13,184
Impairment expense	5,412
Total operating expenses	41,538	47,610
Operating loss	(36,634)	(42,436)
Other income (expense)
Interest income	388	697
Interest expense	(16,590)	(10,742)
Change in fair value of the Convertible Loan	(120,963)	31,399
Gain on debt and the Convertible Loan extinguishments		2,166
Total other income (expense), net	(137,165)	23,520
Net loss	$ (173,799)	$ (18,916)
Per share information:
Net loss per share, basic	$ (4.8)	$ (0.52)
Weighted average shares outstanding, basic	36,239,253	36,160,848
Net loss per share, diluted	$ (4.8)	$ (0.89)
Weighted average shares outstanding, diluted	36,239,253	59,059,971